243 related articles for article (PubMed ID: 31272246)
1. The NK1 receptor antagonist serlopitant for treatment of chronic pruritus.
Ständer S; Spellman MC; Kwon P; Yosipovitch G
Expert Opin Investig Drugs; 2019 Aug; 28(8):659-666. PubMed ID: 31272246
[No Abstract] [Full Text] [Related]
2. Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial.
Ständer S; Kwon P; Hirman J; Perlman AJ; Weisshaar E; Metz M; Luger TA;
J Am Acad Dermatol; 2019 May; 80(5):1395-1402. PubMed ID: 30894279
[TBL] [Abstract][Full Text] [Related]
3. Serlopitant for the treatment of chronic pruritus: Results of a randomized, multicenter, placebo-controlled phase 2 clinical trial.
Yosipovitch G; Ständer S; Kerby MB; Larrick JW; Perlman AJ; Schnipper EF; Zhang X; Tang JY; Luger T; Steinhoff M
J Am Acad Dermatol; 2018 May; 78(5):882-891.e10. PubMed ID: 29462657
[TBL] [Abstract][Full Text] [Related]
4. Serlopitant for psoriatic pruritus: A phase 2 randomized, double-blind, placebo-controlled clinical trial.
Pariser DM; Bagel J; Lebwohl M; Yosipovitch G; Chien E; Spellman MC
J Am Acad Dermatol; 2020 Jun; 82(6):1314-1320. PubMed ID: 32007513
[TBL] [Abstract][Full Text] [Related]
5. Substance P and neurokinin 1 receptor are new targets for the treatment of chronic pruritus.
Ständer S; Yosipovitch G
Br J Dermatol; 2019 Nov; 181(5):932-938. PubMed ID: 31016733
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 trial of a neurokinin-1 receptor antagonist for the treatment of chronic itch in patients with epidermolysis bullosa: A randomized clinical trial.
Chiou AS; Choi S; Barriga M; Dutt-Singkh Y; Solis DC; Nazaroff J; Bailey-Healy I; Li S; Shu K; Joing M; Kwon P; Tang JY
J Am Acad Dermatol; 2020 Jun; 82(6):1415-1421. PubMed ID: 31541747
[TBL] [Abstract][Full Text] [Related]
7. Novel drugs for the treatment of chronic pruritus.
Pereira MP; Ständer S
Expert Opin Investig Drugs; 2018 Dec; 27(12):981-988. PubMed ID: 30426802
[TBL] [Abstract][Full Text] [Related]
8. Benefits and harms of NK
Yang Y; Guo L; Chen Z; Jiang X; Liu Y
Dermatol Ther; 2021 Jan; 34(1):e14698. PubMed ID: 33368902
[TBL] [Abstract][Full Text] [Related]
9. Medical treatment of pruritus.
Ständer S; Weisshaar E
Expert Opin Emerg Drugs; 2012 Sep; 17(3):335-45. PubMed ID: 22870909
[TBL] [Abstract][Full Text] [Related]
10. Neurokinin 1 Receptor Antagonists for Pruritus.
Alam M; Buddenkotte J; Ahmad F; Steinhoff M
Drugs; 2021 Apr; 81(6):621-634. PubMed ID: 33675531
[TBL] [Abstract][Full Text] [Related]
11. Aprepitant in Anti-histamine-refractory Chronic Nodular Prurigo: A Multicentre, Randomized, Double-blind, Placebo-controlled, Cross-over, Phase-II trial (APREPRU).
Tsianakas A; Zeidler C; Riepe C; Borowski M; Forner C; Gerss J; Metz M; Staubach P; Raap U; Kaatz M; Urban M; Luger TA; Ständer S
Acta Derm Venereol; 2019 Apr; 99(4):379-385. PubMed ID: 30653242
[TBL] [Abstract][Full Text] [Related]
12. Emerging drugs for the treatment of pruritus.
Ständer S; Weisshaar E; Raap U
Expert Opin Emerg Drugs; 2015 Sep; 20(3):515-21. PubMed ID: 26027744
[TBL] [Abstract][Full Text] [Related]
13. The NK1 receptor antagonist aprepitant attenuates NK1 agonist-induced scratching behaviour in the gerbil after intra-dermal, topical or oral administration.
Costantini VJ; Corsi M; Dünstl G; Bettelini L; Zonzini L; Gerrard P
Exp Dermatol; 2015 Apr; 24(4):312-4. PubMed ID: 25650546
[TBL] [Abstract][Full Text] [Related]
14. Safety considerations when using drugs to treat pruritus.
Fourzali K; Yosipovitch G
Expert Opin Drug Saf; 2020 Apr; 19(4):467-477. PubMed ID: 32064980
[No Abstract] [Full Text] [Related]
15. A multicenter, double-blind, randomized, placebo controlled trial of a neurokinin-1 receptor antagonist for overactive bladder.
Frenkl TL; Zhu H; Reiss T; Seltzer O; Rosenberg E; Green S
J Urol; 2010 Aug; 184(2):616-22. PubMed ID: 20639026
[TBL] [Abstract][Full Text] [Related]
16. A patient with concurrent prurigo nodularis and squamous cell carcinomas of keratoacanthoma type: The role of aprepitant in diagnostic clarity.
Jedlowski PM; Fazel M; Foshee JP; Curiel-Lewandrowski C
JAAD Case Rep; 2020 Jan; 6(1):3-5. PubMed ID: 31956685
[No Abstract] [Full Text] [Related]
17. Itch Management: Treatments under Development.
Pereira MP; Ständer S
Curr Probl Dermatol; 2016; 50():71-6. PubMed ID: 27578074
[TBL] [Abstract][Full Text] [Related]
18. Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy.
Ständer S; Siepmann D; Herrgott I; Sunderkötter C; Luger TA
PLoS One; 2010 Jun; 5(6):e10968. PubMed ID: 20532044
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic potential of biologics in prurigo nodularis.
Müller S; Bieber T; Ständer S
Expert Opin Biol Ther; 2022 Jan; 22(1):47-58. PubMed ID: 34289753
[TBL] [Abstract][Full Text] [Related]
20. Emerging drugs for the treatment of chronic pruritic diseases.
Fourzali K; Golpanian RS; Yosipovitch G
Expert Opin Emerg Drugs; 2020 Sep; 25(3):273-284. PubMed ID: 32715798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]